European Respiratory Journal最新文献

{"title":"Viewpoint: a critique of pulmonary vascular resistance to define severe pulmonary hypertension.","authors":"Robert Naeije,Ari Chaouat,Michael R Pinsky","doi":"10.1183/13993003.00409-2025","DOIUrl":"https://doi.org/10.1183/13993003.00409-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"16 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999-2002.","authors":"Javier Perez-Garcia, Dennis Khodasevich, Sara De Matteis, Mary B Rice, Belinda L Needham, David H Rehkopf, Andres Cardenas","doi":"10.1183/13993003.00293-2025","DOIUrl":"10.1183/13993003.00293-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.","authors":"Kevin Sheng-Kai Ma,Bethany Brumbaugh,Rebecca R Saff,Wanda Phipatanakul,Serena Yun-Chen Tsai,Mike Westmeijer,Allison Holt,Joseph Ebriani,Carlos A Camargo,Steven T Chen","doi":"10.1183/13993003.00139-2025","DOIUrl":"https://doi.org/10.1183/13993003.00139-2025","url":null,"abstract":"BACKGROUNDDupilumab is approved for treatment of atopic dermatitis, asthma and other allergic diseases, including atopic dermatitis. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among asthma patients treated with dupilumab.METHODSThis population-based cohort study included U.S. patients with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids [ICS] plus long-acting beta agonists [LABA], or ICS/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and the secondary outcomes were other malignancies and all-cause mortality.RESULTSA total of 14 936 dupilumab-treated and 734 126 ICS/LABA-treated asthma patients were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (n=54 versus 43 cases, hazard ratio [HR]=1.79, 95% CI 1.19, 2.71), especially T and natural killer (NK) cell lymphomas (n=19 versus <10, HR=4.580, 95% CI 1.82, 11.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (n=328 versus 793, HR=0.65, 95% CI 0.57, 0.74).CONCLUSIONSDupilumab treatment was associated with lower all-cause mortality among asthma patients despite increased risk of lymphoma, particularly T and NK cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"14 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracorporeal photopheresis for the prevention of rejection after lung transplantation.","authors":"Guanyu Yang,Hailong Bing","doi":"10.1183/13993003.02478-2024","DOIUrl":"https://doi.org/10.1183/13993003.02478-2024","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"16 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How systemic antibodies prevent severe respiratory infections in COPD: A Viewpoint.","authors":"Carl Persson","doi":"10.1183/13993003.00896-2025","DOIUrl":"https://doi.org/10.1183/13993003.00896-2025","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"44 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mannose-6-phosphate attenuates acute lung injury by competitive release of acid sphingomyelinase from the mannose-6-phosphate receptor in endothelial caveolae.","authors":"Tian Jiang, Rudi Samapati, Sergej Klassen, Supandi Winoto-Morbach, Zain H Mohamed, Rolf Göggel, Jun Yin, Lijie Tan, Christoph Arenz, Sabrina Schulz, Lasti Erfinanda, Robert Preissner, Szandor Simmons, Stefan Schütze, Stefan Uhlig, Wolfgang M Kuebler","doi":"10.1183/13993003.00003-2024","DOIUrl":"10.1183/13993003.00003-2024","url":null,"abstract":"<p><strong>Background: </strong>Platelet-activating factor (PAF)-induced pulmonary endothelial barrier failure is mediated by acid sphingomyelinase (ASM) translocation to caveolae. ASM, however, lacks a transmembrane domain for anchoring inside caveolae. We hypothesised that ASM anchors to cation-independent mannose-6-phosphate (M6P) receptor (CI-M6PR) in caveolae, from where it can be competitively released by M6P.</p><p><strong>Methods: </strong>We explored ASM-CI-M6PR interactions using co-immunoprecipitation and proximity ligation assay in isolated lungs and human pulmonary microvascular endothelial cells. ASM release by M6P was determined in human pulmonary microvascular endothelial cells, isolated lungs and <i>in vivo</i>. The effects of M6P on 1) PAF-induced lung oedema formation and endothelial Ca²⁺ concentration and 2) lung injury in acid instilled, overventilated mouse lungs were examined. ASM levels were measured in serum and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. The TriNetX database was probed for associations of ASM-inhibiting tricyclic antidepressants with outcomes.</p><p><strong>Results: </strong>Co-immunoprecipitation and proximity ligation assay revealed an ASM interaction with CI-M6PR in endothelial caveolae, which was further increased by PAF. M6P, but not glucose-6-phosphate, caused ASM release, thereby decreasing ASM content and activity in caveolae <i>in vitro</i>, <i>in situ</i> and <i>in vivo</i>. Analogously, M6P, yet not glucose-6-phosphate, attenuated PAF-induced endothelial Ca²⁺ influx and lung oedema <i>in situ</i>, and acute lung injury <i>in vivo</i>. ASM levels were increased in serum but not bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome. Use of tricyclic antidepressants was associated with better outcomes in patients with severe respiratory infections.</p><p><strong>Conclusions: </strong>CI-M6PR anchors ASM in caveolae. M6P may hence present a promising target in ASM-related lung injury and oedema.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): Results of a multi-centre randomised controlled trial.","authors":"Barry J Plant, Gisli G Einarsson, Kevin F Deasy, Darren Dahly, Pradeep K Singh, Peter J Barry, Christopher H Goss, Isabelle Fajac, Tamara Vagg, Isabelle Durieu, Evelyn Flanagan, Grace O'Callaghan, Clémence Martin, Pierre-Régis Burgel, Charles S Haworth, R Andres Floto, Damian G Downey, Lieven J Dupont, Andrew M Jones, J Stuart Elborn, Joseph A Eustace, Marcus A Mall, Michael M Tunney","doi":"10.1183/13993003.02443-2024","DOIUrl":"https://doi.org/10.1183/13993003.02443-2024","url":null,"abstract":"<p><strong>Background: </strong>This study explores the effectiveness and safety of microbiome-directed-antimicrobial-therapy <i>versus</i> usual-antimicrobial-therapy in adult cystic fibrosis pulmonary exacerbations.</p><p><strong>Methods: </strong>A multi-centre two-arm parallel randomised control trial conducted across Europe/North-America enrolled 223 participants (January 2015 - August 2017). All participants were chronically colonised with <i>Pseudomonas aeruginosa</i> and were randomised 1:1 into two study-arms. The \"usual-therapy group\" received 2-weeks of IV ceftazidime 3g thrice-daily (for allergies: aztreonam 2g thrice-daily) and tobramycin 5-10mg·kg^-1 once-daily. The \"microbiome-directed group\" received the same usual-therapy plus an additional antibiotic with greatest presumed activity against the 2nd, 3rd and 4th most abundant genera present in the sputum microbiome, selected by a Consensus Expert Treatment Panel. The primary outcome was change in percentage of predicted FEV₁ (ppFEV₁) at 14 days post initiation of antibiotics. Secondary outcomes examined ppFEV₁ at 7 days, 28 days, and 3 months; time-to-next exacerbation; symptom burden at 7 days; Health Related Quality of Life (HRQoL) at 28 days; and number of exacerbations and IV antibiotic days at 12 months.</p><p><strong>Results: </strong>149 participants had an eligible exacerbation (usual-therapy n=83, microbiome-directed therapy n=66). There was no difference between the groups for ppFEV₁ at day 14 (-1.1%, 95%CI -3.9 to 1.7; p=0.46), or ppFEV₁ measured at other time-points, or for time-to-next exacerbation (microbiome-directed <i>versus</i> usual-therapy Hazard Ratio 0.91 [95%CI 0.60 to 1.38; p=0.66]). The microbiome-directed group trended to have more IV days (median 42 <i>versus</i> 28; p=0.08) and more subsequent exacerbations (median 3 <i>versus</i> 2; p=0.044) the following year. There were no appreciable differences in symptom burden; however, HRQoL sub-scores were consistently worse in the microbiome-directed group (-4.3 points <i>versus</i> usual therapy (95%CI -8.3 to -0.3, p=0.033).</p><p><strong>Conclusion: </strong>The addition of a third antibiotic based on sputum microbiome sequencing analysis did not result in improved clinical outcomes.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-life exposure to mixture of phenols and respiratory health in pre-school children.","authors":"Alicia Guillien, Sam Bayat, Inès Amine, Anne Boudier, Sarah Lyon-Caen, Joane Quentin, Zoltán Hantos, Séverine Valmary-Degano, Amrit K Sakhi, Cathrine Thomsen, Claire Philippat, Rémy Slama, Valérie Siroux","doi":"10.1183/13993003.02265-2024","DOIUrl":"https://doi.org/10.1183/13993003.02265-2024","url":null,"abstract":"<p><strong>Introduction: </strong>Exposure to synthetic phenols is suspected of affecting child respiratory health, but epidemiological findings are not consistent and studies on exposure during infancy are lacking. We aimed to investigate the association between exposure to a mixture of phenols in pregnancy and in infancy and children's respiratory health.</p><p><strong>Methods: </strong>Among 363 mother-child pairs from the SEPAGES cohort, twelve phenols were measured in weekly-pooled urine samples collected twice during pregnancy (second (T2) and third (T3) trimesters) and in infancy (2 months (M2) and 1 year (Y1)). Children's lung function was assessed through tidal breathing flow-volume loops and nitrogen multiple-breath washout at M2, and standard and intra-breath oscillometry at 3 years. Time-specific phenol exposure profiles were identified through cluster analysis and then studied in association with respiratory health using adjusted regression models.</p><p><strong>Results: </strong>Two exposure profiles were identified at each point in time, characterized by low <i>versus</i> high levels of several phenol compounds. Overall, high exposure profiles were associated with altered oscillometry parameters at 3 years, particularly between high exposure profile at T2 and higher frequency-dependence of resistance (R7-19) and lower volume-dependence of reactance (ΔX); high exposure profile at M2 and lower reactance at 7 Hz (X7), and high exposure at Y1 and higher area of the reactance curve (AX), resistance at 7 Hz (R7), and volume-dependence of resistance (ΔR).</p><p><strong>Conclusion: </strong>This study relying on repeated and accurate assessments of phenols exposure provides evidence of the deleterious effects of early-life exposures to a mixture of phenols on lung function in pre-school children.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct mural cells and fibroblasts promote pathogenic plasma cell accumulation in idiopathic pulmonary fibrosis.","authors":"Zhi Yang, Gaoyuan Cao, Xiaosheng Tan, Sarah Orfanos, Joseph Jude, Gaetan Barbet, Steven S An, Dianhua Jiang, Reynold A Panettieri, Qi Yang","doi":"10.1183/13993003.01114-2024","DOIUrl":"10.1183/13993003.01114-2024","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is characterised by significant but poorly understood immune and antibody responses. This study examines the spatial transcriptomes and microenvironmental niches of antibody-producing plasma cells and tertiary lymphoid structures in IPF lungs, and the molecular pathways influencing antibody accumulation and pulmonary fibrosis.</p><p><strong>Methods: </strong>Explant lung tissues from IPF patients and control normal lungs were used for spatial transcriptome assays and validating RNAscope and immunofluorescence assays. Fibroblasts derived from IPF and control lungs were examined for their ability to attract plasma cells. Neutralising antibodies were administered to investigate molecules affecting pulmonary plasma cell accumulation and fibrosis in bleomycin-treated mice.</p><p><strong>Results: </strong>Human IPF lungs exhibited a remarkably widespread distribution of plasma cells and local antibodies in the fibrotic regions, disseminating from plasma cell-generating tertiary lymphoid structures. Novel mural cells wrapped the vessels in tertiary lymphoid structure regions, expressing C-C motif chemokine receptor 7 (CCR7) ligands that attracted T-cells into tertiary lymphoid structures to promote plasma cell generation. Distinct IPF-associated fibroblasts further secreted C-X-C motif chemokine ligand 12 (CXCL12), providing an extramedullary niche to foster the dissemination and accumulation of plasma cells in the fibrotic regions. Neutralisation of CCR7 ligands or CXCL12 reduced plasma cell and local antibody accumulation in the lungs of bleomycin-treated mice, leading to reduced transforming growth factor β concentrations and alleviated pulmonary fibrosis.</p><p><strong>Conclusions: </strong>Plasma cells and local antibodies are widely distributed in the fibrotic regions of IPF lungs. Distinct subsets of IPF-associated mural cells and fibroblasts promote pathological plasma cell and antibody accumulation. These findings have potential implications for strategies aimed at targeting immune and antibody responses to combat IPF.</p>","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarification of author disclosures for four <i>ERJ</i> articles.","authors":"","doi":"10.1183/13993003.50414-2020","DOIUrl":"https://doi.org/10.1183/13993003.50414-2020","url":null,"abstract":"","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"65 6","pages":""},"PeriodicalIF":16.6,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}